Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting Phase II NCT06321302

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy — Active Not Recruiting • Phase II • NCT06321302.

📅 17 Apr 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Phase II
NCT ID
NCT06321302
Start
2024-05-15
Completion
2027-04-30
ClinicaliQ Trial Snapshot
  • A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy — Active Not Recruiting • Phase II • NCT06321302.
  • Trial testing whether BI 764524 injection helps moderate-to-severe diabetic retinopathy, comparing different dosing schedules against sham control.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Participants in groups 1, 2, and 3 get BI 764524. Over 1 year, they get a different number of injections of the same dose of…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn